OK HB1503

Defines "biological product," "biosimilar," and "interchangeable" using the same meanings from Section 351 of the federal Public Health Service Act.

Permits pharmacists to dispense a substitute biological product only if the FDA has determined the substitute is biosimilar and interchangeable with the prescribed product.

Requires pharmacists to notify patients of substitution and the retail price difference between products, and inform patients they may refuse the substitution.

Mandates pharmacists notify the prescribing practitioner in writing or electronically within 5 days and maintain records of substitutions for at least 2 years.

Requires the State Board of Pharmacy to maintain a current list of FDA-approved biosimilar and interchangeable biological products on its public website.

Becomes effective November 1, 2015.